Eupraxia Pharmaceuticals (EPRX) Earnings Date, Estimates & Call Transcripts $3.90 +0.06 (+1.56%) As of 04/24/2025 03:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Eupraxia Pharmaceuticals Earnings Summary Upcoming Q1 Earnings DateMay. 14Before Market OpensEstimatedConsensus EPS (Mar. 20) -$0.20 Actual EPS (Mar. 20) -$0.21 Missed By -$0.01 Eupraxia Pharmaceuticals announced Q4 2024 earnings on March 20, 2025, reporting an EPS of -$0.21, which missed the consensus estimate of -$0.20 by $0.01. With a trailing EPS of -$0.76, Eupraxia Pharmaceuticals' earnings are expected to grow next year, from ($0.67) to ($0.60) per share. Q4 2024 Earnings ResourcesQ4 2024 Earnings ReportEPRX Upcoming EarningsEupraxia Pharmaceuticals' next earnings date is estimated for Wednesday, May 14, 2025, based on past reporting schedules. Get Eupraxia Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataEPRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Eupraxia Pharmaceuticals Analyst EPS EstimatesCurrent Year EPS Consensus Estimate ($0.67) EPSNext Year EPS Consensus Estimate ($0.60) EPS Eupraxia Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/14/2025(Estimated)--------3/20/2025Q4 2024-$0.20-$0.21 -$0.01-$0.21--11/7/2024---$0.17 -$0.17-$0.17--8/7/2024Q2 2024--$0.17 -$0.17-$0.17--5/8/2024Q1 2024--$0.21 -$0.21-$0.21--4/1/2024Q4 2023--$0.17 -$0.17-$0.17--11/14/2023Q3 2023--$0.26 -$0.26-$0.26--8/11/2023Q2 2023--$0.36 -$0.36-$0.36--5/11/2023Q1 2023--$0.23 -$0.23-$0.23-- Eupraxia Pharmaceuticals Earnings - Frequently Asked Questions When is Eupraxia Pharmaceuticals's earnings date? Eupraxia Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 14th, 2025 based off last year's report dates. Learn more on EPRX's earnings history. Did Eupraxia Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Eupraxia Pharmaceuticals (NASDAQ:EPRX) missed the analysts' consensus estimate of ($0.20) by $0.01 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. EPRX's actual earnings. How much profit does Eupraxia Pharmaceuticals generate each year? Eupraxia Pharmaceuticals (NASDAQ:EPRX) has a recorded net income of -$28.22 million. EPRX has generated -$0.76 earnings per share over the last four quarters. What is Eupraxia Pharmaceuticals's EPS forecast for next year? Eupraxia Pharmaceuticals's earnings are expected to grow from ($0.67) per share to ($0.60) per share in the next year. More Earnings Resources from MarketBeat Related Companies CorMedix Earnings Results Organogenesis Earnings Results Upstream Bio Earnings Results Immatics Earnings Results Sionna Therapeutics Earnings Results Prothena Earnings Results Kura Oncology Earnings Results Akebia Therapeutics Earnings Results Tyra Biosciences Earnings Results Stoke Therapeutics Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Tesla Earnings Miss, But Musk Refocuses and Bulls ReactQualcomm’s Range Narrows Ahead of Earnings as Bulls Step InWhy It May Be Time to Buy CrowdStrike Stock Heading Into EarningsCan IBM’s Q1 Earnings Spark a Breakout for the Stock? This page (NASDAQ:EPRX) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
